The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Diagnostics and treatment outcomes from primary CBCL
Amra Osmancevic, MD, PhD, University of Gothenburg, Gothenburg, Sweden, talks on the findings of a retrospective study investigating the diagnostics and treatment outcomes of patients with primary cutaneous B-cell lymphoma (CBCL). Dr Osmancevic reports that all patients in the study had indolent disease with skin manifestations varying from plaques to tumors. Furthermore, Dr Osmancevic describes how two patients were found to have malignant melanoma and comments on the impact of this finding. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
